

## **Exhibit 22**

*State of California ex. rel. Ven-A-Care of the Florida Keys, Inc. v.  
Abbott Laboratories, Inc., et al.*

Exhibit to the Declaration of Rita Hanscom in Support of  
Plaintiffs' Opposition to Dey, Inc. and Dey, L.P.'s Motion for Partial Summary Judgment

Hillblom, Douglas B.

September 23, 2008

Sacramento, CA

Page 1

UNITED STATES DISTRICT COURT

DISTRICT OF MASSACHUSETTS

IN RE PHARMACEUTICAL INDUSTRY

AVERAGE WHOLESALE PRICE

LITIGATION

\_\_\_\_\_/

THIS DOCUMENT RELATES TO MDL No. 1456

State of California, ex rel. Civil Action:

Ven-A-Care v. Abbott 01-12258-PBS

Laboratories, Inc., et al.

\_\_\_\_\_/

--oOo--

TUESDAY, SEPTEMBER 23, 2008

--oOo--

VIDEOTAPED DEPOSITION OF

DOUGLAS B. HILLBLOM

--oOo--

Reported By: CAROL NYGARD DROBNY, CSR No. 4018

Registered Merit Reporter

Henderson Legal Services, Inc.

202-220-4158

www.hendersonlegalservices.com

59a7f9f9-30c2-4b26-a88f-b90f6ae9a028

Hillblom, Douglas B.

September 23, 2008

Sacramento, CA

Page 348

1 Q. To your knowledge did the -- during your  
2 time at the Department of Health Services did the  
3 Department of Health Services have an expectation  
4 that drug manufacturers would report the AWP's to  
5 First DataBank honestly and truthfully?

6 MR. BUEKER: Objection to form.

7 MS. BERWANGER: Objection to form.

8 MR. ROBBEN: I thought he wasn't a  
9 30(b)(6) witness.

10 THE WITNESS: My understanding is that  
11 the expectation of the Department was that the --  
12 the data supplied was the appropriate data, that it  
13 was accurate.

14 BY MR. PAUL:

15 Q. To your knowledge has any pharmaceutical  
16 manufacturer ever sent -- during your tenure at DHS  
17 ever sent DHS written information stating what the  
18 manufacturer's AWP was based on?

19 A. No.

20 Q. So that would -- your answer would  
21 obviously apply to Mylan, Sandoz, Geneva, Dey,  
22 Warrick, and Schering, since they're drug

Hillblom, Douglas B.

September 23, 2008

Sacramento, CA

Page 349

1 manufacturers?

2 A. Yes.

3 Q. To your knowledge has any drug  
4 manufacturer ever sent any written information to  
5 DHS during your tenure there stating the difference  
6 between that manufacturer's reported AWP and the  
7 actual acquisition costs of Medi-Cal providers?

8 MR. BUEKER: Objection to form.

9 MS. BERWANGER: Objection.

10 MR. ROBBEN: Join.

11 THE WITNESS: Not that I'm aware of.

12 BY MR. PAUL:

13 Q. Turn briefly back to Exhibit 22, page  
14 23, which is Bates number 0071611.

15 A. Page 23?

16 Q. And I think you provided some testimony  
17 in response to some questions from Mr. Bueker  
18 earlier today about pages 23 and 24 of Exhibit 22;  
19 is that correct?

20 A. That's -- what I recall.

21 Q. And he asked you some questions about  
22 some of the statements that are listed as cons, and